SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements.
Merel van der MeulenAmir H Z NajafabadiDaniel J LobattoCornelie D AndelaThea P M Vliet VlielandAlberto M PereiraWouter R van FurthNienke R BiermaszPublished in: Endocrine (2020)
On a group level, SF-12 can reliably reproduce MCS in pituitary patients, although PCS is less well correlated. However, individual differences between SF-36 and SF-12 can be large. For pituitary diseases, alternative strategies are needed for concise, but comprehensive patient-reported outcome measurement.